EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Shakagami Jujin
Country: Saint Lucia
Language: English (Spanish)
Genre: Relationship
Published (Last): 19 August 2005
Pages: 236
PDF File Size: 6.70 Mb
ePub File Size: 10.2 Mb
ISBN: 192-6-33523-359-2
Downloads: 27552
Price: Free* [*Free Regsitration Required]
Uploader: Goltitaxe

The primary outcome measure was all-cause treatment discontinuation.

The principal investigators are Prof. This effort represents the first independently designed trans-European schizophrenia treatment trial. These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics. What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range.

This outcome is assessed at regular time intervals until 12 months after recruitment. Eligibility Participant inclusion criteria 1. Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder 2.

Quality of life 6. However, we cannot euufest that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. Result of results found for within. Rationale and design of the trial. Intolerance to one of the drugs in this study; 4.

Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia.

  COMO FAO PARA UNIR DOIS ARQUIVOS PDF

Intolerance to one of the drugs in this study 4. Retention to efuest study drug, which is the time that the patient stays on the randomised drug within the study dose range.

At regular studu intervals patients are followed-up until 12 months after recruitment: SchizophreniaSchizophreniform disorderSchizoaffective disorder. Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions.

Genetic determinants of response to antipsychotic drugs 9. Plain English Summary Not provided at time of registration Trial website http: Patients and their treating physicians euest not blinded to the assigned treatment. Evid Based Ment Health.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Ethics approval received from the local medical ethics committee. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: Home Who are we? Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study sfudy Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Results and Publications Publication eufet dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1.

We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug tsudy or who are aggressive or suicidal or less likely to be compliant with treatment.

We did stidy open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries. PfizerAstraZenecaSanofi-Aventis. At present, more than patients have been recruited and randomized in the following countries: What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

  MACARIO JUAN RULFO PDF

Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone. Natural history of schizophrenia.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

The presence of one or more of the contra-indications against any of the study drugs. The Lancet ; At regular time intervals patients are followed-up until 12 months after recruitment: Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness eufeet with first-generation antipsychotic drugs is still debated.

Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: The study should be finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics. The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

Previous Trial Back to results Next Trial. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0.

Schizophreniform or schizoaffective disorder; 3. Diagnosis of schizophrenia; 2. Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested.

Author: admin